Compare AstraZeneca plc (AZN) vs ProShares Ultra Gold ETF (UGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs ProShares Ultra Gold ETF — how do they compare? AstraZeneca plc trades at $157.44 (market cap $248.14B), while ProShares Ultra Gold ETF trades at $52.54. The key difference: AstraZeneca plc pays a 2.01% dividend while ProShares Ultra Gold ETF pays none, and ProShares Ultra Gold ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | UGL | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $209.48 | $85.62 |
52-Week Low | $147.06 | $34.37 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
UGL is trading at $52.81, up 2.13% with a bullish technical signal from moving averages, though oscillators show bearish divergence. The stock faces resistance at $53 with support at $51. Recent gold market strength from inflation data and geopolitical tensions provides positive momentum, though financial ratios remain unavailable for fundamental assessment.
The outlook for UGL appears cautiously optimistic given gold's recent performance, but investment decisions require verified financial data currently missing. Key risks include gold price volatility and reliance on broader commodity trends. Analyst consensus and institutional positioning data are needed for comprehensive evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About ProShares Ultra Gold ETF
UGL is a leveraged ETF that seeks daily investment results, before fees and expenses, that correspond to two times (2x) the daily performance of the Bloomberg Gold Subindex. It is a tactical tool designed for sophisticated investors to magnify short-term bullish views on gold prices through the use of futures and swap contracts, rather than holding physical bullion.
Read more on UGL →
